08:00 , Nov 25, 2013 |  BC Week In Review  |  Company News

Cornerstone Therapeutics sales and marketing update

Cornerstone launched Bethkis tobramycin inhalation solution in the U.S. to manage Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF). The wholesale acquisition cost for a 28-day supply of Bethkis is $5,675. The recommended dose...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Activaero, Chiesi deal

The companies partnered to evaluate a drug-device combination product using Activaero's Flow and Volume Controlled Inhalation Technology (FAVORITE) and Chiesi's Bethkis inhaled tobramycin solution to treat cystic fibrosis (CF). The partners expect to complete in...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Company News

Chiesi, Cornerstone Therapeutics sales and marketing update

Chiesi granted Cornerstone U.S. rights to market Bethkis tobramycin inhalation solution. The inhaled tobramycin solution was approved last month to manage Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF). Chiesi will receive $1 million...